Elocom lotion

Land: Armenien

Sprog: engelsk

Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiv bestanddel:

mometasone (mometasone furoate)

Tilgængelig fra:

Famar Montreal Inc.

ATC-kode:

D07AC13

INN (International Name):

mometasone (mometasone furoate)

Dosering:

1mg/g

Lægemiddelform:

lotion

Enheder i pakken:

30ml plastic vial-dropper

Recept type:

Prescription

Autorisation status:

Registered

Autorisation dato:

2018-08-07

Produktets egenskaber

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
ELOCOM
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 g of lotion contains:
_active ingredient: _ mometasone furoate 1 mg.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lotion.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATION(S)
Elocom (mometasone furoate) Lotion 0.1%, are indicated for the
relief
of
the
inflammatory
and
pruritic
manifestations
of
corticosteroid-responsive
dermatoses
such
as
psoriasis
and
atopic
dermatitis. The lotion formulation may be applied to scalp lesions.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Apply a few drops of Elocom lotion to the affected skin areas
including scalp sites once daily;
massage gently and thoroughly until medication disappears.
Do not use occlusive dressings.
4.3
CONTRAINDICATIONS
Elocom Lotion 0.1% are contraindicated in patients who are sensitive
to mometasone furoate, to
other corticosteroids or to any component of these preparations. For a
complete listing, see the
“_Composition_” section.
Topical steroids are contraindicated in untreated fungal, bacterial
and viral (i.e. herpes simplex,
chicken pox and vaccinia) infections involving the skin.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
General
Systemic absorption of topical corticosteroids will be increased if
extensive body surface areas are
treated or if the occlusive technique is used. Suitable precautions
should be taken under these
conditions or when long-term use is anticipated, particularly in
infants and children.
Pediatric patients may demonstrate greater susceptibility to topical
corticosteroid-induced HPA axis
suppression and Cushing’s syndrome than mature patients because of a
larger skin surface area to
body weight ratio. Use of topical corticosteroids in children should
be limited to the least amount
compatible with an effective therapeutic regimen. Chronic
corticosteroid therapy may interfere with
growth and development of children.
Patients should be advised to inform subsequent physicians of the